Insider Trading Activity RXi Pharmaceuticals Corp (NASDAQ:RXII) – CEO Bought 10,000 shares of Stock

195

Insider Trading Activity For RXi Pharmaceuticals Corp (NASDAQ:RXII)

Geert Cauwenbergh , CEO of RXi Pharmaceuticals Corp (NASDAQ:RXII) reportedly Bought 10,000 shares of the company’s stock at an average price of 0.77 for a total transaction amount of $7,700.00 SEC Form

Insider Trading History For RXi Pharmaceuticals Corp (NASDAQ:RXII)

  • On 8/29/2013 Curtis Lockshin, Director, bought 1,000 with an average share price of $3.70 per share and the total transaction amounting to $3,700.00. View SEC Filing
  • On 10/9/2013 Geert Cauwenbergh, CEO, bought 1,000 with an average share price of $3.15 per share and the total transaction amounting to $3,150.00. View SEC Filing
  • On 10/23/2013 Geert Cauwenbergh, CEO, bought 1,000 with an average share price of $3.34 per share and the total transaction amounting to $3,340.00. View SEC Filing
  • On 10/31/2013 Geert Cauwenbergh, CEO, bought 1,000 with an average share price of $3.17 per share and the total transaction amounting to $3,170.00. View SEC Filing
  • On 6/4/2014 Geert Cauwenbergh, CEO, bought 2,000 with an average share price of $2.94 per share and the total transaction amounting to $5,880.00. View SEC Filing
  • On 6/9/2014 Geert Cauwenbergh, CEO, bought 1,000 with an average share price of $3.05 per share and the total transaction amounting to $3,050.00. View SEC Filing
  • On 6/19/2014 Geert Cauwenbergh, CEO, bought 2,000 with an average share price of $2.98 per share and the total transaction amounting to $5,960.00. View SEC Filing
  • Analyst Ratings For RXi Pharmaceuticals Corp (NASDAQ:RXII)
    These are 1 Buy Rating .
    The current consensus rating for RXi Pharmaceuticals Corp (NASDAQ:RXII) is Buy (Score: 3.00) with a consensus target price of $2.61 , a potential (238.62% upside)

    Analyst Ratings History For RXi Pharmaceuticals Corp (NASDAQ:RXII)

    • On 6/7/2016 HC Wainwright Initiated Coverage of rating Buy with a price target of $3.50 with a price target of $2.35 to $1.71

    About RXi Pharmaceuticals Corp (NASDAQ:RXII)
    RXi Pharmaceuticals Corporation is a clinical-stage ribonucleic acid (RNA) interference (RNAi) company developing therapeutics in dermatology and ophthalmology that address unmet medical needs. The Company’s development programs are based on its self-delivering RNAi (sd-rxRNA) platform and Samcyprone, a topical immunomodulator. Its clinical development programs include RXI-109, an sd-rxRNA, for the treatment of dermal and ocular scarring, and Samcyprone for the treatment of such disorders as warts, alopecia areata, non-malignant skin tumors and cutaneous metastases of melanoma. Its pipeline is focused on approximately three areas, including dermatology, ophthalmology and cosmetic product development. Its RNAi therapies are designed to silence, or down-regulate, the expression of a specific gene that may be over-expressed in a disease condition and its immunotherapy agent treats diseases by inducing, enhancing or suppressing an immune response.

    Recent Trading Activity for RXi Pharmaceuticals Corp (NASDAQ:RXII)
    Shares of RXi Pharmaceuticals Corp closed the previous trading session at 0.741 down -0.028 -3.65% with 858,699 shares trading hands.

    An ad to help with our costs